# KU Leuven

> KU Leuven is a VC fund in Leuven backing Biotechnology and Medical. See 14 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Leuven, Belgium
- Total investments: 14
- Last investment: Sep 2025
- Lead investor: 14%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/ku_leuven
- X (Twitter): https://twitter.com/LeuvenU
- Website: http://www.kuleuven.be/english
- Facebook: https://www.facebook.com/KULeuven/

KU Leuven is a VC fund in Leuven focused on Biotechnology and Medical. Founded in 1425, the multidisciplinary and research-driven University of Leuven (KU Leuven) has been a centre of learning for almost six centuries. Situated in Belgium, in the heart of Western Europe, KU Leuven has been a centre of learning for nearly six centuries. Today, it is Belgium's largest university and, founded in 1425, one of theoldest and most renowned universities in Europe. As a leading European research university and co-founder of the League of European Research Universities (LERU), KU Leuven offers a wide variety of international master’s programmes, all supported by high-quality, innovative, interdisciplinary research. Since its founding, KU Leuven has been based in the city that shares its name. Leuven is a pleasant, safe and bustling student town, where centuries-rich history meets cutting-edge science. The university also offers degree programmes at campuses in 11 Belgian cities, including Brussels, Ghent and Antwerp.

## Contacts

5 contacts available for KU Leuven. Shizune tracks 14 team members at KU Leuven. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/university-of-leuven?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 43% |
| Medical | 3 | 21% |
| Software | 2 | 14% |
| Therapeutics | 2 | 14% |
| Manufacturing | 2 | 14% |

26 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 5 | 36% |
| Series A | 4 | 29% |
| Series B | 3 | 21% |
| Venture - Series Unknown | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 11 | 79% |
| Brazil | 1 | 7% |
| Ireland | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Luc De Raedt | Professor | 0 | https://shizune.co/investors/profile/luc-de-raedt |
| Mathy Vanhoef | PhD researcher | 0 | https://shizune.co/investors/profile/mathy-vanhoef |
| Tim Wood | Research Associate | 0 | https://shizune.co/investors/profile/tim-wood-a4bd |
| Daniel Berckmans | Full Professor | 0 | https://shizune.co/investors/profile/daniel-berckmans |
| Emin Oguz Inci | Postdoctoral Researcher | 0 | https://shizune.co/investors/profile/emin-oguz-inci-e4b3 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aspect Analytics | Aspect Analytics offers consultancy services, home-grown software, development of workflows, and customization of software. | $11.7M | Series A | Sep 09, 2025 |  |
| Magics Technologies | Magics Technologies is a nuclear research center that develops autonomous machines for sustainable energy sources. | $11.1M | Venture - Series Unknown | Apr 16, 2025 |  |
| Imcyse | Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on theadministration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases. | $25.7M | Series B | Feb 17, 2021 |  |
| reMYND | Their Contract Research Organization (CRO) helps their clients assess the effects of their experimental Alzheimer treatments in their proprietary mouse models.They serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. They have provided pivotal in-vivo proof-of-concept data for several candidate drugscurrently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept. | $14.6M | Series B | Jan 21, 2021 |  |
| Virovet | ViroVet is a pioneering company dedicated to the development of disruptive and innovative technologies for the control of viral diseases in livestock, with antiviral drugs for respiratory disease complexes and innovative vaccines for viral infections in swine leading the pipeline. The livestock industry is a 100+ billion-euro industry. Viraldiseases cost producers billions every year in losses and threaten the world supply of animal protein.The strategy of ViroVet is to provide novel solutions to be used alone or in combination with vaccines and biosecurity measures in order to provide livestock producers, national governments and international organizations with a multi-faceted arsenal of virus control weapons against endemic and epizootic viral diseases.It is clear that with the growing world population there is an increased demand for more protein-rich diets. With the increasing density of the livestock industry, the intensifying global trade and climate changes, there is an ever increased risk for the global spread of viral diseases, severely damaging livestock industry.ViroVet has already enlisted the support of a number of key opinion leaders (KOLs) in livestock medicine confirming the extensive market for antiviral drugs and novel vaccines addressing the challenges of spreading viral diseases. KOLs feel that ViroVet’s products have the potential to reduce the use of antibiotics and revolutionize the livestock industry worldwide. | $6.6M | Series B | May 28, 2020 |  |
| Montis Biosciences | Montis Biosciences is develops novel immune-oncology therapeutics targeting the intersection between vascular dysfunction and immune suppression to treat solid tumours. | $9.1M | Seed | Feb 20, 2020 |  |
| Pulsify Medical | Pulsify Medical is a digital medical technology company | $2.9M | Seed | Oct 15, 2019 |  |
| MyCellHub | MyCellHub.com is a pre-startup from the KULeuven in the biotherapeutics industry that aspires to reform the way cell production processes are organised. With a regulatory compliant Saas-platform for data management and analytics, we increase the efficiency of your manufacturing processes, provide actionable insights via cell culture specificprocess analytics and facilitate regulatory compliance by means of a real-time audit trail and automated batch records. | $1.1M | Seed | Sep 12, 2019 |  |
| nextAuth | nextAuth is a spin-off of Europe’s most innovative university. With three PhDs in applied cryptography working for nextAuth, nextAuth continuously innovates its product. As such, our customers will always have the most secure user authentication solution on the market. By leveraging state-of-the-art cryptography, usability and security are nolonger a trade-off. nextAuth provides strong multi-factor authentication combined with an almost-seamless user experience. |  | Seed | Mar 18, 2019 |  |
| reMYND | Their Contract Research Organization (CRO) helps their clients assess the effects of their experimental Alzheimer treatments in their proprietary mouse models.They serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. They have provided pivotal in-vivo proof-of-concept data for several candidate drugscurrently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept. | $13.2M | Series B | Dec 18, 2018 |  |

10 of 14 investments shown.

## Co-investors
- [Gemma Frisius Fund](https://shizune.co/investors/profile/gemma-frisius-fund) — VC Fund, 7 deals together
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund, 6 deals together
- [BNP Paribas Fortis](https://shizune.co/investors/profile/bnp-paribas-fortis) — VC Fund, 2 deals together
- [Capricorn Partners](https://shizune.co/investors/profile/capricorn-partners) — VC Fund, 2 deals together
- [Korys](https://shizune.co/investors/profile/korys) — VC Fund, 2 deals together
- [Meusinvest (Noshaq)](https://shizune.co/investors/profile/meusinvest) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does KU Leuven invest in?

KU Leuven invests primarily in Biotechnology, Medical and Software startups, most often at Seed and Series A stage. Most of the 14 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact KU Leuven?

Public channels for KU Leuven include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at KU Leuven?

The team at KU Leuven includes Luc De Raedt (Professor), Mathy Vanhoef (PhD researcher) and Tim Wood (Research Associate), among 14 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co